Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $516K fell 99.5% year over year, behind the -88.4% change in trailing-twelve-month revenue. Sequentially, it fell 67.6% from the prior quarter. Over 3 fiscal years it compounded at +23.9% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $3.72M (-96.9%) for the fiscal year ending Dec 2026, a slowdown from the -6.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$516K-67.6% QoQ
Last fiscal yearDec 2025
$120.77M-6.3% YoY
LTMMar 2026
$23.14M-88.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.5%-96.9%+2.6 pp
1 year-6.3%-96.9%-90.6 pp
3-year CAGR+23.9%-31.7%-55.6 pp
5-year CAGR-5.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
120.77M USD
Year-over-year change
-6.3%
4-year CAGR
+56.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -88.4% is the 9th highest of 10, against a peer median of -1.1%.
  • Over three fiscal years its annual growth of +23.9% compares with a peer median of +5.1%.
ATRA Competitors
Revenue for ATRA and competitors
Company Period LTM YoY 3-year CAGR
MGNXMacroGenics, Inc.LTM Mar 2026$157.08M USD+3.1%-0.1%
STROSutro Biopharma, Inc.LTM Mar 2026$99.61M USD+49.9%+14.8%
CSBRChampions Oncology, Inc.LTM Jan 2026$57.94M USD-1.1%+5.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$23.14M USD-88.4%+23.9%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.94M USD+115.4%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.12M USD+1199.6%+69.0%
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-78.3%+15.3%
CLNNClene Inc.LTM Mar 2026$134K USD-61.7%-24.9%
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-9.6%
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD——
Peer median (excluding ATRA) —-1.1%+5.1%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.